Carlsbad, California (ots/PRNewswire) - Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2006. As a ...
Basel, Switzerland (ots/PRNewswire) - - New International Trial Called PROGRESS Starts in 15 Countries Roche today announces the start of a large multinational trial in patients with difficult-to-cure genotype 1 hepatitis C. This international study will evaluate the effect of PEGASYS (peginterferon ...
St. Paul, Minnesota (ots/PRNewswire) - - For the attention of News and Business Editors 3M Health Care announced today the launch of a new Medical Diagnostics business unit that will focus on developing and commercializing rapid diagnostic product solutions for the detection of key infectious pathogens, ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has received approval from United States Adopted Name (USAN) for naming of its lead immunosuppressive drug, ISA247. The name, voclosporin, is now being reviewed by the International Nonproprietary Name (INN) expert committee. The INN is scheduled to publish the proposed list of ...
Basel, Switzerland (ots/PRNewswire) - - New global educational resources spotlight renal anaemia, a common under-recognized complication of Chronic Kidney Disease To help support health professionals who play a key role in educating and managing patients with Chronic Kidney Disease (CKD), Roche today announced the launch of AnaemiaWorld.com, a major new centralized online resource. AnaemiaWorld.com is believed ...
Brussels (ots/PRNewswire) - Ansell Healthcare, a world leader in barrier protection, welcomes the European Commission's recently announced strategy to reduce occupational accidents and diseases in the European Union by 25% by 2012. Ansell Healthcare, a producer of both medical and industrial gloves, claims that ...
Basingstoke, England (ots/PRNewswire) - Clinical Solutions, a leading British provider of software solutions to the healthcare market, has been selected to provide call centre management and clinical decision support software for the Portuguese Public Health System. The software will be used by staff manning Portugal's first national health helpline to record patient calls and provide information to aid advice for ...
Round Lake, Illinois (ots/PRNewswire) - Fenwal Inc. today announced its launch as an independent company. The new corporation is formed upon Baxter Healthcare Corporation completing the sale of its Transfusion Therapies business to Texas Pacific Group (TPG) and Maverick Capital, Ltd. Established by TPG ...
Ottawa, Canada (ots/PRNewswire) - - Expanded Facility in Fleurus, Belgium to be Leading Player in Supply of Glucotrace(R) for Growing Market MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals for molecular imaging, is investing U.S. $5.8 million / (euro) 4.5 million to expand its production facility in Fleurus, Belgium to ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. annual report 28.02.2007 Pfaeffikon SZ, 28 February 2007 --- In the fiscal year ending 31 December 2006 shaPE made further progress as documented by the share price which gained 12% to a record level of CHF 243.00. shaPE achieved a gross ...
Alderley Park, England (ots/PRNewswire) - - A Phase III international, parallel group, randomised, double-blind study of vandetanib in combination with pemetrexed for advanced non-small cell lung cancer (NSCLC) after failure of first line anti-cancer therapy AstraZeneca today announced that a new Phase ...
Indianapolis (ots/PRNewswire) - - Trial will help better identify appropriate patient, define the benefit-risk profile in this population Eli Lilly and Company (NYSE: LLY) today announced plans for a new clinical study of Xigris(R) (drotrecogin alfa [activated]). The trial is designed to help clinicians better identify severe sepsis patients at high risk of death who are more likely to benefit from this ...
New York (ots/PRNewswire) - Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in Denmark -- that prohibits the sale of a generic version of Lipitor by generics manufacturer Ranbaxy. The injunction, issued by the Bailiff's Court of the Copenhagen City Court in Denmark and ...
New York (ots/PRNewswire) - - Celebrex to be Available in Europe for the Treatment of Ankylosing Spondylitis, a Debilitating Form of Arthritis Pfizer Inc announced today that 17 European countries agreed to extend the Celebrex (celecoxib capsules) label to include symptomatic relief in the treatment of ankylosing spondylitis (in adults), a form of arthritis that affects the spine. Once each country updates ...
Irvine, California (ots/PRNewswire) - - Update on Recent Events IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today reported preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2006. Revenue was approximately US$10 million (unaudited) for the fourth quarter of 2006, representing a 16% increase over revenue of the fourth quarter of 2005. For the full year 2006, ...
Lyon, France (ots/PRNewswire) - - New Vaccine Will Help Improve Public Health in Japanese Encephalitis Endemic Countries Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today it has entered into an agreement with Acambis plc to license a single dose vaccine against Japanese encephalitis (JE), ChimeriVaxTM-JE, to help improve ...
New York (ots/PRNewswire) - - If Approved, Maraviroc will be the First in a New Class of Medications Available for HIV Treatment Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would ...
Basel (ots/PRNewswire) - - First Worldwide Test of Public's Knowledge About Kidneys On-line Quiz Launches Today Our kidneys are amazing organs that play a crucial role in keeping us alive and well - but how much do we really know about them and do we know what can happen if disease sets in? This is the ...
Abbott Park, Illinois (ots/PRNewswire) - - First-of-its-Kind Study Designed to Learn More About Cardiovascular Disease in Women Abbott today announced plans to initiate the world's first drug-eluting stent clinical trial solely in women. The SPIRIT WOMEN trial will aim to increase understanding of how ...
Ingelheim, Germany (ots/PRNewswire) - Long-term data from the Nevirapine/Efavirenz/Abacavir (NEFA) study demonstrate that patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen containing Viramune(R) (nevirapine) or efavirenz achieved comparable efficacy and safety to their previous regimen ...
Vancouver, Canada (ots/PRNewswire) - Perceptronix Medical Inc. ("Perceptronix") today announced its participation in a research project to detect early oral cancer lesions through a new initiative inside the BC Oral Cancer Prevention Program. This Program is bringing together a network of dentists, researchers and technology companies to develop early screening ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 22.01.2007 Pfaeffikon SZ, 22 January 2007 --- The Board of Directors of shaPE Capital AG today announced that within the limits of the capital increase all subscription rights have been ...
Basel, Switzerland (ots/PRNewswire) - - New Phase III Data Presented at the American Society of Clinical Oncology Gastrointestinal Symposium (ASCO GI) continue to demonstrate the excellent efficacy of two of Roche's innovative cancer drugs Xeloda and Avastin, which offer improved survival for patients ...
Vancouver, Canada (ots/PRNewswire) - Perceptronix CEO Carl Roy announced the appointment of Ms. Rohini Hira to the position of Vice President Sales and Marketing effective December 15th, 2006. Ms. Hira has the vision and experience to commercialize Perceptronix' early cancer detection products and services in Canada, the US and the EU. Ms. Hira's career spans ...
New York (ots/PRNewswire) - - Full marketing authorization and extension of indication to first-line treatment of advanced and/or metastatic renal cell carcinoma (MRCC) - First multiple receptor tyrosine kinase inhibitor to be approved in the EU for first-line use in MRCC Pfizer Inc said today that ...
Philadelphia, Pennsylvania (ots/PRNewswire) - - Study to Compare Immunogencity of GSK's Cervical Cancer Candidate Vaccine, CERVARIX(R), to Merck's Gardasil(R) GlaxoSmithKline (NYSE: GSK) announced today the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate vaccine, CERVARIX(R), versus ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that its partner, Lux Biosciences, has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for ISA247, referred to as LX211 by Lux, for the treatment of non-infectious posterior, intermediate and ...
Pompey, France (ots/PRNewswire) - Groupe Novasep has been acquired for an enterprise value of EUR 425 million by its management and by a financial investor group composed of Gilde Buy Out, Banexi Capital Partenaires, BNP Paribas. The acquisition has been signed on November 29th, 2006 and completed on January 9th ...
Calgary, Alberta (ots/PRNewswire) - - Canadian Biotechnology Company Takes Next Significant Step Towards Advancing its Product to the Clinic - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, today ...
Alderley Park, England (ots/PRNewswire) - - For Non-US Healthcare Press Only AstraZeneca today announced RECENTIN(TM) as the global trademark for AZD2171, its oral, highly potent and selective vascular endothelial growth factor (VEGF) signalling inhibitor. AZD2171 is currently in Phase II/III development for advanced non-small cell lung cancer (NSCLC) and ...